this issue, Swem et al. (2008) dissect the function of the LuxN receptor by determining several residues that are important for the binding of the receptor to AI-1 or a small-molecule antagonist that they discovered. They also report mutations that affect the balance between the "on" and "off" state of the receptor independent of ligand ( Figure 1 ).
LuxN is one of the three membranebound receptors mediating quorum sensing in V. harveyi. In the "on" state, LuxN is a kinase that autophosphorylates, leading to a signaling cascade that culminates in the degradation of LuxR mRNA and an absence of bioluminescence (the dark phenotype). With autoinducer bound, however, the LuxN receptor is biased toward a phosphatase activity that ultimately leads to the accumulation of LuxR and a bioluminescent phenotype.
Given that the LuxN receptor is membrane bound, has no known three-dimensional structure (other than its predicted membrane topology), and is at the top of a cascade involving several other proteins and small RNAs, the authors chose to explore the effects of sitespecific changes to the receptor in vivo. The schematic depicts the quorum-sensing receptor LuxN with its predicted topology consisting of nine transmembrane helices. Periplasmic loops are designated P1-P4, and cytoplasmic loops are designated C1-C4. The approximate locations of mutations that have a negative effect on AI-1 binding and/or signaling (conferring a dark phenotype) are indicated in red. Mutations that increased sensitivity to AI-1 are shown in blue. The mutation found to interfere with the binding of the antagonist C450-0730 is shown in green.
the signal to the downstream parts of the signaling pathway. In the case of smallmolecule antagonists the case is equally complex, with possible explanations of a dark phenotype including allosteric inhibition of transduction, competition with AI-1 binding, and binding-induced changes in the balance between kinase and phosphatase activities. In order to test the specific roles of these mutants and chemical compounds, the authors collected doseresponse curves in which the bioluminescent response was measured with increasing concentrations of AI-1. These dose-response curves were collected for 30 mutants that passed the original screen of more than 30,000 mutants and for several of the mutants that suppressed the activity of the antagonist C450-0730. A kinetic model for the bioluminescent response (the eventual readout of the receptor) as a function of the concentration of agonist and antagonist was used to decipher specific kinetic/thermodynamic roles from these dose-response curves:
where p on is the percentage of maximal luminescent response, and f is the freeenergy difference between the on and off states of the receptor in units of k B T (where k B is the Boltzmann constant, which relates energy to an absolute temperature T). The equation used to model f as a function of binding and dissociation constants for AI-1 and the antagonist C450-0730 is as follows:
where ∆ε is the free-energy gap between the "on" and "off" states. With this kinetic model in hand, the authors show that they can adjust the kinetic parameters associated with mutant receptors to "collapse" (or fit) the dose-response curve of the mutant onto the wild-type curve. For example, for some mutants, the simplest way to reconcile the doseresponse curve with the wild-type receptor is to adjust the ∆ε parameter, whereas for others, adjusting the dissociation constant K AI-1 off / K AI-1 on was the most parsimonious way of getting the mutant curve to agree with the wild-type curve. This allowed the authors to determine, for example, that several of the mutants with dark phenotypes affected the affinity of LuxN for AI-1, whereas other mutations (such as F163A) biased the receptor toward the "on" state independently of AI-1 binding affinity. Using this mathematical model, they were also able to separate mutations that suppressed antagonism by C450-0730 into two categories: those that increased AI-1 binding affinity (S184N, R245L, G271D) and those that interfered with C450-0730 binding (I209F). Finally, the effects of these suppressor mutants were shown to be roughly additive and epistatic to mutations that interfere with AI-1 binding or bias the receptor to the "on" state. For example, they showed that the mutation F163A, which required 378-fold more AI-1 to switch to phosphatase activity than the wild-type receptor, was effectively reversed by engineering a protein with the four suppressor mutations simultaneously. Thus, the kinetic parameters discovered by this method stood the ultimate test, that of being used to design new receptors with a phenotype matching site-specific predictions.
Although there is still much to learn about LuxN, its downstream pathway, and variations on this system found in other bacteria, this study is an exquisitely complete work that provides explicit functional information about LuxN at amino acid resolution. Moreover, the work represents a useful general strategy for combining in vivo genetic screens with chemical biology and mathematical modeling. Integrating these techniques provides unambiguous information for a receptor that could otherwise prove challenging to work with in the lab.
